Payment overview · 2025
General Payments
$406.29
19 reported records · 12 companies
Healthcare provider profile · identity verified
Christopher Michael Morgan, CRNP
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Family · BIRMINGHAM, AL · NPI 1891341335
Verified facts
What the public records show
CMS Open Payments records show Christopher Michael Morgan, CRNP received $406.29 in general payments during 2025 across 19 reported records.
United Therapeutics Corporation accounted for 13.1% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 14 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Verquvo.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Eliquis by this doctor in 2024.
Merck Sharp & Dohme LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VERQUVO as an associated drug or biological on 38060 records involving 12268 distinct recipient NPIs. Public Medicare Part D data also shows 13 claims for Verquvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 341 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $53.05 | 13.1% | 2 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $52.68 | 13.0% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $49.69 | 12.2% | 3 | 2025 |
| HEARTFLOW, INC. | Unresolved — no canonical attribution shown | $43.86 | 10.8% | 1 | 2025 |
| Actelion Pharmaceuticals US, Inc. | Unresolved — no canonical attribution shown | $43.65 | 10.7% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $33.51 | 8.2% | 2 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $31.92 | 7.9% | 1 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $28.16 | 6.9% | 2 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $21.07 | 5.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $18.92 | 4.7% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $15.75 | 3.9% | 1 | 2025 |
| SCPHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $14.03 | 3.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $406.29 | 19 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $53.05 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $52.68 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $49.69 | 3 | 2025 |
Source payment records
|
|||||
| FFRct Normalized: ffrct |
Device | HEARTFLOW, INC. | $43.86 | 1 | 2025 |
Source payment records
|
|||||
| UPTRAVI Normalized: uptravi |
Drug | Actelion Pharmaceuticals US, Inc. | $43.65 | 2 | 2025 |
Source payment records
|
|||||
| VYNDAQEL Normalized: vyndaqel |
Drug | PFIZER INC. | $33.51 | 2 | 2025 |
Source payment records
|
|||||
| FARAPULSE Normalized: farapulse |
Device | Boston Scientific Corporation | $31.92 | 1 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $28.16 | 2 | 2025 |
Source payment records
|
|||||
| OPSYNVI Normalized: opsynvi |
Drug | Actelion Pharmaceuticals US, Inc. | $24.20 | 1 | 2025 |
Source payment records
|
|||||
| CAMZYOS Normalized: camzyos |
Drug | E.R. Squibb & Sons, L.L.C. | $21.07 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $18.92 | 1 | 2025 |
Source payment records
|
|||||
| AREXVY Normalized: arexvy |
Biological | GlaxoSmithKline, LLC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| SHINGRIX Normalized: shingrix |
Biological | GlaxoSmithKline, LLC. | $15.75 | 1 | 2025 |
Source payment records
|
|||||
| FUROSCIX Normalized: furoscix |
Drug | SCPHARMACEUTICALS INC. | $14.03 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| VERQUVO verquvo |
2025 | Verquvo | 2024 | 13 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
341 | 92 |
| Merck Sharp & Dohme LLC Exact reporting entity; no affiliate inference |
2025 | VERQUVO open payments reported associated product |
CMS Open Payments — General Payments 38060 supporting records · 12268 recipient NPIs · example record 1237992208 |
Verquvo · 2024 Exact normalized brand match · 1 Part D row |
13 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
341 | 92 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 341 | 92 |
| Metoprolol Succinate | Metoprolol Succinate | 251 | 75 |
| Dofetilide | Dofetilide | 212 | 39 |
| Carvedilol | Carvedilol | 203 | 69 |
| Flecainide Acetate | Flecainide Acetate | 179 | 55 |
| Amlodipine Besylate | Amlodipine Besylate | 119 | 32 |
| Losartan Potassium | Losartan Potassium | 110 | 34 |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 106 | 25 |
| Hydralazine Hcl | Hydralazine Hcl | 94 | 25 |
| Xarelto | Rivaroxaban | 93 | 26 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 92 | 28 |
| Multaq | Dronedarone Hcl | 65 | 15 |
| Repatha Sureclick | Evolocumab | 65 | suppressed |
| Atorvastatin Calcium | Atorvastatin Calcium | 64 | 24 |
| Ezetimibe | Ezetimibe | 49 | suppressed |
| Sotalol | Sotalol Hcl | 49 | 17 |
| Lisinopril | Lisinopril | 46 | 16 |
| Clopidogrel | Clopidogrel Bisulfate | 43 | 17 |
| Entresto | Sacubitril/Valsartan | 42 | 18 |
| Pantoprazole Sodium | Pantoprazole Sodium | 38 | 37 |
| Chlorthalidone | Chlorthalidone | 37 | 14 |
| Furosemide | Furosemide | 35 | 12 |
| Metoprolol Tartrate | Metoprolol Tartrate | 32 | 13 |
| Potassium Chloride | Potassium Chloride | 32 | 14 |
| Repatha Syringe | Evolocumab | 29 | suppressed |
| Digoxin | Digoxin | 28 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 26 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 22 | suppressed |
| Ranolazine Er | Ranolazine | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Clonidine | Clonidine | 19 | suppressed |
| Simvastatin | Simvastatin | 19 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 18 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 17 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 17 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 17 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 16 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 15 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 14 | suppressed |
| Nexlizet | Bempedoic Acid/Ezetimibe | 14 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 14 | suppressed |
| Spironolactone | Spironolactone | 13 | suppressed |
| Verquvo | Vericiguat | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 11 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $406.29 · 19 records | United Therapeutics Corporation | AMVUTTRA, AREXVY, CAMZYOS, FARAPULSE, FFRct, FUROSCIX, JARDIANCE, OPSYNVI, SHINGRIX, Tyvaso, UPTRAVI, VERQUVO, VYNDAQEL, Wegovy | 3 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Verquvo play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error